应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
KLRS Kalaris Therapeutics Inc.
交易中 03-16 15:18:32 EDT
8.49
-0.18
-2.13%
最高
8.96
最低
8.20
成交量
5.55万
今开
8.96
昨收
8.67
日振幅
8.77%
总市值
1.59亿
流通市值
3,656万
总股本
1,870万
成交额
46.68万
换手率
1.29%
流通股本
430.93万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Kalaris Therapeutics公布TH103在未接受治疗的血管新生性AMD中初步1a期数据积极
美股速递 · 2025-12-18
Kalaris Therapeutics公布TH103在未接受治疗的血管新生性AMD中初步1a期数据积极
Kalaris Therapeutics:第一阶段单次递增剂量试验预计年底前将披露初步临床数据
美股速递 · 2025-11-12
Kalaris Therapeutics:第一阶段单次递增剂量试验预计年底前将披露初步临床数据
Kalaris Therapeutics正在招募TH103治疗新生血管性年龄相关性黄斑变性的1B/2期多剂量递增研究
美股速递 · 2025-09-15
Kalaris Therapeutics正在招募TH103治疗新生血管性年龄相关性黄斑变性的1B/2期多剂量递增研究
加载更多
公司概况
公司名称:
Kalaris Therapeutics Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Kalaris Therapeutics, Inc.成立于2013年8月16日,是特拉华州的一家有限责任公司。该公司是一家领先的临床晚期细胞治疗公司,开发高度创新的异基因T细胞疗法来治疗和预防毁灭性的病毒性疾病。该公司的创新和专有的病毒特异性T细胞(VST)治疗平台能够产生现成的VST,旨在恢复T细胞缺陷患者的免疫力。
发行价格:
--
{"stockData":{"symbol":"KLRS","market":"US","secType":"STK","nameCN":"Kalaris Therapeutics Inc.","latestPrice":8.485,"timestamp":1773688709619,"preClose":8.67,"halted":0,"volume":55451,"delay":0,"changeRate":-0.021337946943483333,"floatShares":4309313,"shares":18702418,"eps":-3.459444,"marketStatus":"交易中","change":-0.185,"latestTime":"03-16 15:18:32 EDT","open":8.96,"high":8.96,"low":8.2,"amount":466805.31588899996,"amplitude":0.087659,"askPrice":8.63,"askSize":100,"bidPrice":8.3,"bidSize":317,"shortable":3,"etf":0,"ttmEps":-3.459444,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1773691200000},"marketStatusCode":2,"adr":0,"listingDate":1596081600000,"exchange":"NASDAQ","adjPreClose":8.67,"postHourTrading":{"tag":"盘后","latestPrice":8.67,"preClose":8.67,"latestTime":"16:10 EDT","volume":129,"amount":1118.43,"timestamp":1773432605217,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.363631},"requestUrl":"/m/hq/s/KLRS","defaultTab":"news","newsList":[{"id":"1142712562","title":"Kalaris Therapeutics公布TH103在未接受治疗的血管新生性AMD中初步1a期数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1142712562","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142712562?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:03","pubTimestamp":1766005389,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics公布TH103在未接受治疗的血管新生性AMD中初步1a期数据积极","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"1117531396","title":"Kalaris Therapeutics:第一阶段单次递增剂量试验预计年底前将披露初步临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1117531396","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117531396?lang=zh_cn&edition=full","pubTime":"2025-11-12 21:08","pubTimestamp":1762952910,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics:第一阶段单次递增剂量试验预计年底前将披露初步临床数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"gpt_icon":0},{"id":"1104736870","title":"Kalaris Therapeutics正在招募TH103治疗新生血管性年龄相关性黄斑变性的1B/2期多剂量递增研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1104736870","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104736870?lang=zh_cn&edition=full","pubTime":"2025-09-15 20:04","pubTimestamp":1757937876,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics目前正在招募TH103用于治疗新生血管性年龄相关性黄斑变性的1B/2期多剂量递增研究患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.allovir.com","stockEarnings":[{"period":"1week","weight":-0.1171},{"period":"1month","weight":-0.1006},{"period":"3month","weight":-0.0225},{"period":"6month","weight":1.2288},{"period":"1year","weight":-0.0493},{"period":"ytd","weight":0.0273}],"compareEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0429},{"period":"3month","weight":-0.0286},{"period":"6month","weight":0.0074},{"period":"1year","weight":0.2011},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kalaris Therapeutics, Inc.成立于2013年8月16日,是特拉华州的一家有限责任公司。该公司是一家领先的临床晚期细胞治疗公司,开发高度创新的异基因T细胞疗法来治疗和预防毁灭性的病毒性疾病。该公司的创新和专有的病毒特异性T细胞(VST)治疗平台能够产生现成的VST,旨在恢复T细胞缺陷患者的免疫力。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.034153},{"month":2,"riseRate":0.833333,"avgChangeRate":0.085302},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.225525},{"month":4,"riseRate":0.4,"avgChangeRate":-0.121971},{"month":5,"riseRate":0.2,"avgChangeRate":-0.129753},{"month":6,"riseRate":0.2,"avgChangeRate":-0.073882},{"month":7,"riseRate":0.6,"avgChangeRate":0.028478},{"month":8,"riseRate":0.833333,"avgChangeRate":0.244693},{"month":9,"riseRate":0.666667,"avgChangeRate":0.05708},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.080715},{"month":11,"riseRate":0.666667,"avgChangeRate":0.065433},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.187434}],"exchange":"NASDAQ","name":"Kalaris Therapeutics Inc.","nameEN":"Kalaris Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kalaris Therapeutics Inc.(KLRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kalaris Therapeutics Inc.(KLRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kalaris Therapeutics Inc.,KLRS,Kalaris Therapeutics Inc.股票,Kalaris Therapeutics Inc.股票老虎,Kalaris Therapeutics Inc.股票老虎国际,Kalaris Therapeutics Inc.行情,Kalaris Therapeutics Inc.股票行情,Kalaris Therapeutics Inc.股价,Kalaris Therapeutics Inc.股市,Kalaris Therapeutics Inc.股票价格,Kalaris Therapeutics Inc.股票交易,Kalaris Therapeutics Inc.股票购买,Kalaris Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kalaris Therapeutics Inc.(KLRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kalaris Therapeutics Inc.(KLRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}